Economic implications of the dynamic relationship between antibiotic use and hospital-acquired infections

Value in Health

Volumn 15, Issue 1, 2012, Pages 87-93

  Kaier, Klaus ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

antibiotic resistance; antibiotic use; externality; hospital acquired infections

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; DISINFECTANT AGENT; LINCOSAMIDE DERIVATIVE; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE; CORRELATION ANALYSIS; COST OF ILLNESS; DISINFECTION; DRUG TREATMENT FAILURE; DRUG UTILIZATION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; STATISTICAL MODEL; TIME SERIES ANALYSIS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; HANDWASHING; HOSPITAL BED CAPACITY; HUMANS; INCIDENCE; LENGTH OF STAY; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MODELS, ECONOMIC; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS;

EID: 84855984604     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.09.005     Document Type: Article

References (59)

1. R.D. Smith, M. Yago, M. Millar, J. Coast Assessing the macroeconomic impact of a healthcare problem: the application of computable general equilibrium analysis to antimicrobial resistance J Health Econ 24 2005 1055 1075 (Pubitemid 41476212)
2. A.F. Shorr Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature Pharmacoeconomics 25 2007 751 768 (Pubitemid 47481640)
3. J.A. Paladino, J.L. Sunderlin, C.S. Price, J.J. Schentag Economic consequences of antimicrobial resistance Surg Infect 3 2002 259 267 (Pubitemid 36013618)
4. E. Klein, R. Laxminarayan, D.L. Smith, C.A. Gilligan Economic incentives and mathematical models of disease Environ Dev Econ 12 2007 707 732 (Pubitemid 47506362)
5. S.B. Levy The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle 1992 Plenum Press New York
6. J.B. Horowitz, H.B. Moehring How property rights and patents affect antibiotic resistance Health Econ 13 2004 575 583 (Pubitemid 38787149)
7. C. Fischer, R. Laxminarayan Sequential development and exploitation of an exhaustible resource: do monopoly rights promote conservation? J Environ Econ Manage 49 2005 500 515 (Pubitemid 40607876)
8. R. Laxminarayan, G.M. Brown Economics of antibiotic resistance: a theory of optimal use J Environ Econ Manage 42 2001 183 206 (Pubitemid 34124508)
9. J. Coast, R.D. Smith, M.R. Millar Superbugs: should antimicrobial resistance be included as a cost in economic evaluation? Health Econ 5 1996 217 226 (Pubitemid 126482627)
10. J. Coast, R.D. Smith, M.R. Millar An economic perspective on policy to reduce antimicrobial resistance Soc Sci Med 46 1998 29 38 (Pubitemid 28014365)
11. E.H. Elbasha Deadweight loss of bacterial resistance due to overtreatment Health Econ 12 2003 125 138 (Pubitemid 36204169)
12. C.E. Phelps Bug/drug resistance: sometimes less is more Med Care 27 1989 194 203
13. R.D. Smith, M. Yago, M. Millar, J. Coast A macroeconomic approach to evaluating policies to contain antimicrobial resistance: a case study of methicillin-resistant Staphylococcus aureus (MRSA) Appl Health Econ Health Policy 5 2006 55 65 (Pubitemid 43927200)
14. K. Kaier, U. Frank Antimikrobielle Resistenz als externer Effekt des Einsatzes von Antibiotika - Zusammenhnge und Implikationen fr die pharmakokonomische Analyse des klinikinternen Einsatzes von Antibiotika Ges kon Qual Manag 14 2009 127 131
15. K. Kaier, U. Frank Measuring the externality of antibacterial use from promoting antimicrobial resistance Pharmacoeconomics 28 2010 1123 1128
16. N.S. Crowcroft, O. Ronveaux, D.L. Monnet, R. Mertens Methicillin- resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals Infect Control Hosp Epidemiol 20 1999 31 36
17. C. MacDougall, J.P. Powell, C.K. Johnson Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals Clin Infect Dis 41 2005 435 440 (Pubitemid 41099634)
18. D.L. Monnet, F.M. MacKenzie, J.M. Lopez-Lozano Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 19962000 Emerg Infect Dis 10 2004 1432 1441 (Pubitemid 39014157)
19. M.A. Aldeyab, D.L. Monnet, J.M. Lopez-Lozano Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus: a time-series analysis J Antimicrob Chemother 62 2008 593 600
20. N. Vernaz, H. Sax, D. Pittet Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile J Antimicrob Chemother 62 2008 601 607
21. K. Kaier, C. Hagist, U. Frank Two time-series analyses of the impact of antibiotic consumption and alcohol-based hand disinfection on the incidences of nosocomial methicillin-resistant Staphylococcus aureus infection and Clostridium difficile infection Infect Control Hosp Epidemiol 30 2009 346 353
22. K. Kaier, U. Frank, C. Hagist The impact of antimicrobial drug consumption and alcohol-based hand rub use on the emergence and spread of extended-spectrum {beta}-lactamase-producing strains: a time-series analysis J Antimicrob Chemother 63 2009 609 614
23. U.S. Jensen, A. Muller, C.T. Brandt Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance J Antimicrob Chemother 65 6 2010 1286 1291
24. A.H. Mutnick, P.R. Rhomberg, H.S. Sader, R.N. Jones Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America J Antimicrob Chemother 53 2 2004 290 296 (Pubitemid 38239964)
25. H. Seppla, T. Klaukka, J. Vuopio-Varkila The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland N Engl J Med 337 1997 441 446 (Pubitemid 27333044)
26. K. Kaier, E. Meyer, U. Frank Epidemiology meets econometrics: using time-series analysis to observe the impact of bed occupancy rates on the spread of multidrug-resistant bacteria J Hosp Infect 76 2010 108 113
27. K. Kaier, D. Luft, M. Dettenkofer Correlations between bed occupancy rates and Clostridium difficile infectionsa time-series analysis Epidemiol Infect 139 2011 482 485
28. M.A. Aldeyab, S. Harbarth, N. Vernaz Quasi-experimental study of the effects of antibiotic use, gastric acid-suppressive agents, and infection control practices on the incidence of Clostridium difficile-associated diarrhea in hospitalized patients Antimicrob Agents Chemother 53 2009 2082 2088
29. D.L. Monnet Methicillin-resistant Staphylococcus aureus and its relationship to antimicrobial use: possible implications for control Infect Control Hosp Epidemiol 19 1998 552 559 (Pubitemid 128472678)
30. D.L. Monnet, J.M. Lopez-Lozano, P. Campillos Making sense of antimicrobial use and resistance surveillance data: application of ARIMA and transfer function models Clin Infect Dis 7 S5 2001 29 36 (Pubitemid 33730216)
31. A.A. Muller, F. Mauny, M. Bertin Relationship between spread of methicillin-resistant Staphylococcus aureus and antimicrobial use in a French university hospital Clin Infect Dis 36 2003 971 978 (Pubitemid 36513280)
32. W.H. Greene Econometric Analysis 1997 Prentice-Hall Upper Saddle River, NJ
33. A. Resch, M. Wilke, C. Fink The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals Eur J Health Econ 10 2009 287 297
34. L.L. Maragakis, E.N. Perencevich, S.E. Cosgrove Clinical and economic burden of antimicrobial resistance Expert Rev Anti Infect Ther 6 2008 751 763
35. R.P. Vonberg, C. Reichardt, M. Behnke Costs of nosocomial Clostridium difficile-associated diarrhoea J Hosp Infect 70 2008 15 20
36. R.C. Spencer Clinical impact and associated costs of Clostridium difficile-associated disease J Antimicrob Chemother 41 Suppl. C 1998 5 12 (Pubitemid 28230294)
37. M.H. Wilcox, J.G. Cunniffe, C. Trundle, C. Redpath Financial burden of hospital-acquired Clostridium difficile infection J Hosp Infect 34 1996 23 30 (Pubitemid 26313206)
38. C.G. Giske, D.L. Monnet, O. Cars, Y. Carmeli Clinical and economic impact of common multidrug-resistant gram-negative bacilli Antimicrob Agents Chemother 52 3 2008 813 821 (Pubitemid 351358357)
39. S.Y. Lee, S. Kotapati, J.L. Kuti Impact of extended spectrum lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study Infect Control Hosp Epidemiol 27 2006 1226 1232 (Pubitemid 44807467)
40. M.J. Schwaber, S. Navon-Venezia, K.S. Kaye Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase-producing Enterobacteriaceae Antimicrob Agents Chemother 50 2006 1257 1262
41. A.R. Salkind, J.M.P.D. Wright Economic burden of adult pharyngitis: the payer's perspective Value Health 11 4 2008 621 627 (Pubitemid 352032805)
42. K. Kaier, U. Frank An econometric view of the dynamic relationship between antibiotic consumption, hand disinfection and methicillin-resistant Staphylococcus aureus J Antimicrob Chemother 63 2009 630 631
43. K. Kaier, U. Frank Relationship between antibiotic consumption and Clostridium difficile-associated diarrheaan epidemiological note Antimicrob Agents Chemother 53 2009 4574 4575
44. E.I. Kritsotakis, A. Christidou, M. Roumbelaki The dynamic relationship between antibiotic use and the incidence of vancomycin-resistant Enterococcus: time-series modelling of 7-year surveillance data in a tertiary-care hospital Clin Microbiol Infect 14 2008 747 754
45. D.P. Rice Estimating the cost of illness Am J Public Health 57 1967 424 440
46. S. Byford, D.J. Torgerson, J. Raftery Economic note: cost of illness studies BMJ 320 2000 1335 (Pubitemid 30245728)
47. D. Rice Cost-of-illness studies: fact or fiction? Lancet 344 1994 1519 1520 (Pubitemid 24357703)
48. R. Tarricone Cost-of-illness analysis: what room in health economics? Health Policy 77 2006 51 63
49. B.S. Bloom, D.J. Bruno, D.Y. Maman, R. Jayadevappa Usefulness of US cost-of-illness studies in healthcare decision making Pharmacoeconomics 19 2001 207 213 (Pubitemid 32176473)
50. M.S. Feldstein Review of B. A. Weisbrod's 'Economics of public health: measuring the economic impact of diseases' Econ J 73 1963 129 130
51. M.A. Koopmanschap Cost-of-illness studies: useful for health policy? Pharmacoeconomics 14 1998 143 148 (Pubitemid 28370825)
52. A. Shiell, K. Gerard, C. Donaldson Cost of illness studies: an aid to decision-making? Health Policy 8 1987 317 323 (Pubitemid 18060163)
53. T.A. Hodgson Cost of illness studies: no aid to decision making? Comments on the second opinion by Shiell et al Health Policy 11 1989 57 60 (Pubitemid 19058902)
54. T.A. Hodgson Costs of illness in cost-effectiveness analysis: a review of the methodology Pharmacoeconomics 6 6 1994 536 552
55. M.R. Baye, R. Maness, S.N. Wiggins Demand systems and the true subindex of the cost of living for pharmaceuticals Appl Econ 29 1997 1179 1189 (Pubitemid 127621695)
56. S.F. Ellison, I. Cockburn, Z. Griliches, J. Hausman Characteristics of demand for pharmaceutical products: an examination of four cephalosporins Rand J Econ 28 1997 426 446 (Pubitemid 127346460)
57. M. Filippini, G. Masiero, K. Moschetti Socioeconomic determinants of regional differences in outpatient antibiotic consumption: evidence from Switzerland Health Policy 78 2006 77 92 (Pubitemid 44108323)
58. M. Filippini, G. Masiero, K. Moschetti Small area variations and welfare loss in the use of outpatient antibiotics Health Econ Policy Law 4 2008 55 77
59. Z. Griliches, I. Cockburn Generics and new goods in pharmaceutical price indexes Am Econ Rev 84 1994 1213 1232